New combo attack on liver metastases from nasopharyngeal cancer enters human trials
NCT ID NCT06788002
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding low-dose radiation to standard chemoimmunotherapy can better control liver tumors in people with nasopharyngeal carcinoma that has spread to the liver. The study will enroll 26 adults aged 18 to 70. Participants will receive low-dose radiation to the liver for 5 days, followed by chemotherapy (gemcitabine and cisplatin) plus an immunotherapy drug (penpulimab). The main goal is to see how long liver tumors stay under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
low-dose radiation, gemcitabine, cisplatin, penpulimab
What this could lead to
If successful, this could offer a more effective first-line treatment for nasopharyngeal cancer that has spread to the liver, potentially improving control of liver tumors and overall survival.
What could go wrong
This is a small, early-phase trial with only 26 participants, so results may not apply to everyone. Adding radiation to chemoimmunotherapy could increase side effects, and the treatment may not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hunan Cancer Hospital
RECRUITINGChangsha, Hunan, 410013, China
-
Hunan Cancer Hospital
RECRUITINGChangsha, Hunan, 410013, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Central Hospital of Shaoyang
RECRUITINGShaoyang, Hunan, 422000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First People's Hospital of Chenzhou
RECRUITINGChenzhou, Hunan, 424300, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Third Xiangya Hospital, Central South University,
RECRUITINGChangsha, Hunan, 410000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Xiangya Hospital of Central South University
RECRUITINGChangsha, Hunan, 410000, China
Contact Email: •••••@•••••
Contact
-
Yueyang Central Hospital
RECRUITINGYueyang, Hunan, 414020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact